ACAAI Updates Guidance for Allergic Reactions to COVID-19 Vaccines
Guidance relates to risks for allergic reactions for mRNA (Moderna and Pfizer) and adenovirus vector (Johnson & Johnson) COVID-19 vaccines
Anaphylaxis
Rates of Acute Allergic Reactions to COVID-19 Vaccines Extremely Low
Most recipients with anaphylaxis had allergy histories, with 31 percent having prior anaphylaxis
Epinephrine Sublingual Film Gets Fast Track Status for Anaphylaxis
AQST-108 is a sublingual film that delivers systemic epinephrine utilizing the Company’s proprietary technology.
FDA: Certain Epinephrine Autoinjector Devices May Have Missing Safety Component
Certain lots of Amneal’s Epinephrine Injection, Autoinjector 0.3mg may not contain the yellow “stop collar” that is necessary for proper dosing of the anaphylaxis treatment, according to the FDA.
Potential EpiPen Device Failure, Use Errors Detailed in Letter to HCPs
Possible device malfunctions and use errors may delay or prevent treatment with EpiPen (epinephrine 0.3mg) and EpiPen Jr (epinephrine 0.15mg) autoinjectors, as well as the authorized generic versions.
Epinephrine More Commonly Used for Venom and Anaphylaxis Than Food Allergy
Epinephrine is more often prescribed for venom allergy and idiopathic anaphylaxis than for food allergy despite its potential as a life-saving drug for allergic reactions.
Corticosteroids Compared for Pre-Infusion Prophylaxis in Patients Receiving Pegloticase for Gout
Compared with intravenous hydrocortisone, IV methylprednisolone appears to be more beneficial as a pre-infusion prophylaxis therapy in patients receiving pegloticase, according to the findings of a recently published review.
AAP: Antihistamine Use for Anaphylaxis May Delay Care Seeking
Odds of delay seeking medical care up with administration of antihistamines to child with anaphylaxis
MPR Weekly Dose Podcast: Episode 5
This week: FDA votes on possible peanut allergy treatment; New risks ID’d with some breast cancer drugs; A topical solution for common warts; Nitrosamine impurity identified in acid suppressant; And news of another e-cigarette related fatality.
FDA Committee Votes on Palforzia for Peanut Allergy
The FDA’s Allergenic Products Advisory Committee voted in favor of the approval of Palforzia (AR101; Aimmune Therapeutics) as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanut in patients 4 through 17 years old with a confirmed diagnosis of peanut allergy.
